1 / 2

SDB-006(695213-59-3) for research, what is it?

APICDMO is the professional manufacturer of SDB-006 and accept Synthetic customization. These products are for scientific research purposes only and not for sale to individuals.<br><br>SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors.It was discovered during research into the related compound SDB-001 which had been sold illicitly as u201c2NE1u201d.SDB-006 metabolism has been described in literature.<br><br>https://www.apicdmo.com/product/695213-59-3/

apicdmo
Download Presentation

SDB-006(695213-59-3) for research, what is it?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SDB-006 CAS:695213-59-3 APICDMO is the professional manufacturer of SDB-006 and accept Synthetic customization. These products are for scientific research purposes only and not for sale to individuals. What is SDB-006? SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors.It was discovered during research into the related compound SDB-001 which had been sold illicitly as “2NE1”.SDB-006 metabolism has been described in literature. SDB-006(695213-59-3) Information Product Name CAS Number Formula Molar mass PubChem CID ChemSpider UNII SDB-006 695213-59-3 C21H24N2O 320.436 g·mol−1 2227769 1665835 MM02A5A302 Reference [1] Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (August 2015). “Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135”. ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407. [2] Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

  2. Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M (January 2018). “The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs”. Drug Testing and Analysis. 10 (7): 1099–1109. doi:10.1002/dta.2362. PMID 29350472. [3] Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). “The synthesis and adamantane-derived indoles: cannabimimetic drugs of abuse”. ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277. pharmacological evaluation of [4] Diao X, Carlier J, Scheidweiler KB, Huestis MA (July 2017). “In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry”. Forensic Toxicology. 35 (2): 252–262. doi:10.1007/s11419-016-0350-9. S2CID 26558377. www.apicdmo.com JINAN APICDMO BIOTECHNOLOGY CO., LIMITED Tel: +8613682461609 Email: emily@apicdmo.com

More Related